Skip to main content
Clinical Trials/CTIS2023-506550-20-00
CTIS2023-506550-20-00
Recruiting
Phase 1

FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)

Odense University Hospital0 sites30 target enrollmentDecember 8, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Metastatic breast cancer
Sponsor
Odense University Hospital
Enrollment
30
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 8, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Women and men aged\=18 years, Diagnosis of distant relapsed MBC (biopsy\-verified) or de novo breast cancer (biopsy verification of primary tumor and disseminated disease at baseline scan), Considered eligible for first\-line systemic treatment, Considered eligible for continuous treatment monitoring by scans, Signed informed consent, Ability to read and understand Danish language

Exclusion Criteria

  • Pregnant or lactating women, Ongoing oncological treatment for another cancer, Exclusively brain metastasis, Allergy to FDG

Outcomes

Primary Outcomes

Not specified

Similar Trials